Description:
Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in
combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a
direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib
combined with dabrafenib alone.
Title
- Brief Title: A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
- Official Title: A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous Melanoma
Clinical Trial IDs
- ORG STUDY ID:
20120238
- NCT ID:
NCT02110355
Conditions
- Advanced Malignancy
- Advanced Solid Tumors
- Cancer
- Oncology
- Oncology Patients
- Tumors
- Melanoma
Interventions
Drug | Synonyms | Arms |
---|
AMG 232 | | AMG 232 with Trametinib |
Trametinib | | AMG 232 with Trametinib |
Dabrafenib | | AMG 232 with Trametinib and Dabrabenib |
Purpose
Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in
combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a
direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib
combined with dabrafenib alone.
Detailed Description
The study will be conducted in 3 parts: Part 1 - Dose Escalation, Part 2 - Dose Expansion and
Part 3, a randomized Phase 2a.
In both part 1 and 2, subjects will be enrolled open-label into 1 of 2 arms. For both Arm 1
and Arm 2, the part 1 dose escalation is aimed at determining an AMG 232 maximum tolerated
dose (MTD) with a fixed dose of the combination drug(s) and evaluating safety, tolerability,
pharmacokinetics and pharmacodynamics of each combination. Part 2 dose expansion will enroll
subjects to receive therapy with a dose and schedule of AMG 232 selected from the
corresponding part 1 dose escalation. In part 2 subjects will be enrolled to confirm safety
and tolerability and to assess clinical activity prior to proceeding to Part 3, Phase 2a. In
Phase 2a, Subjects will be randomized open-label in a 1:1 ratio to receive AMG 232 in
combination with trametinib plus dabrafenib versus trametinib plus dabrafenib alone.
Only Part 1 of the study was enrolled and the study did not proceed into Phase 2.
Trial Arms
Name | Type | Description | Interventions |
---|
AMG 232 with Trametinib and Dabrabenib | Experimental | Arm 1 of Part 1 and 2 and Part 3 | - AMG 232
- Trametinib
- Dabrafenib
|
AMG 232 with Trametinib | Experimental | Arm 2 of Part 1 and 2 | |
Trametinib and Dabrafenib | Active Comparator | Part 3 | |
Eligibility Criteria
Inclusion Criteria: Subjects must have histologically or cytologically confirmed metastatic
cutaneous or mucosal melanoma, Able to swallow and retain orally administered medication,
Adequate hematological, renal, hepatic, and coagulation laboratory assessments Exclusion
Criteria: Clinically significant bleeding within 4 weeks of screening, Current use of
warfarin, factor Xa inhibitors, and direct thrombin inhibitors, Infection requiring
anti-infective treatments within 1 week of study enrollment, Anti-tumor therapy, Major
surgery within 28 days
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Subject incidence of treatment-emergent adverse events, Results of safety laboratory tests, vital sign measurements, ECG measurements, PK parameters; Progression-free Survival Rate |
Time Frame: | 36 months |
Safety Issue: | |
Description: | Incidence and grade of treatment-emergent adverse events, including dose-limiting toxicities; AMG 232, trametinib, dabrafenib, and metabolite PK parameters; progression-free Survival |
Secondary Outcome Measures
Measure: | Time to and duration of overall response and duration of stable disease measured by CT or MRI and assessed per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, Progression-free and Overall Survival |
Time Frame: | 36 months |
Safety Issue: | |
Description: | Objective Tumor Response |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Completed |
Lead Sponsor: | Kartos Therapeutics, Inc. |
Trial Keywords
Last Updated
March 26, 2021